These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 16767199

  • 1. Editorial: update on the modern management of wet age-related macular degeneration.
    Devenyi RG.
    Can J Ophthalmol; 2006 Apr; 41(2):133-8. PubMed ID: 16767199
    [No Abstract] [Full Text] [Related]

  • 2. The new face of age-related macular degeneration.
    Giuliari GP, Ciardella AP.
    Can J Ophthalmol; 2007 Aug; 42(4):629-30. PubMed ID: 17641716
    [No Abstract] [Full Text] [Related]

  • 3. Controversies in the treatment of wet age-related macular degeneration.
    Moreno SF, Paloma JB.
    Am J Ophthalmol; 2008 May; 145(5):937; author reply 938. PubMed ID: 18435977
    [No Abstract] [Full Text] [Related]

  • 4. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.
    Bom Aggio F, Eid Farah M, Melo GB.
    Acta Ophthalmol Scand; 2006 Oct; 84(5):713-4. PubMed ID: 16965511
    [No Abstract] [Full Text] [Related]

  • 5. Intravitreal avastin: the low cost alternative to lucentis?
    Rosenfeld PJ.
    Am J Ophthalmol; 2006 Jul; 142(1):141-3. PubMed ID: 16815262
    [No Abstract] [Full Text] [Related]

  • 6. Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ziemssen F, Heiduschka P, Schraermeyer U, Tübingen Bevacizumab Study Group.
    Retina; 2007 Oct; 27(8):1154-6; author reply 1156-8. PubMed ID: 18040264
    [No Abstract] [Full Text] [Related]

  • 7. Intravitreal bevacizumab for parapapillary choroidal neovascularization due to exudative age-related macular degeneration.
    Jonas JB, Tao Y, Rensch F.
    Acta Ophthalmol; 2011 Feb; 89(1):e105-7. PubMed ID: 20064119
    [No Abstract] [Full Text] [Related]

  • 8. Comparing ranibizumab with bevacizumab.
    Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S.
    Ophthalmology; 2011 Mar; 118(3):600-600.e2. PubMed ID: 21376243
    [No Abstract] [Full Text] [Related]

  • 9. Anti-Vascular Endothelial Growth Factor Injection for Exudative Age-related Macular Degeneration in Patients with Vitreo-Macular Traction.
    Querques G.
    Am J Ophthalmol; 2009 Feb; 147(2):375-6; author reply 376-7. PubMed ID: 19166716
    [No Abstract] [Full Text] [Related]

  • 10. Avastin and new treatments for AMD: where are we?
    Freeman WR, Falkenstein I.
    Retina; 2006 Oct; 26(8):853-8. PubMed ID: 17031283
    [No Abstract] [Full Text] [Related]

  • 11. The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system.
    Spaide RF.
    Am J Ophthalmol; 2009 Jul; 148(1):1-3. PubMed ID: 19540983
    [No Abstract] [Full Text] [Related]

  • 12. Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab.
    Barbazetto I, Saroj N, Shapiro H, Wong P, Freund KB.
    Retina; 2010 Oct; 30(9):1376-85. PubMed ID: 20683380
    [Abstract] [Full Text] [Related]

  • 13. Anti-VEGF therapy: riding the wave of change.
    Hunyor AP.
    Clin Exp Ophthalmol; 2008 Jul; 36(5):401-2. PubMed ID: 18925912
    [No Abstract] [Full Text] [Related]

  • 14. Photodynamic therapy in the anti-VEGF era.
    Fine HF.
    Br J Ophthalmol; 2007 Jun; 91(6):707-8. PubMed ID: 17510474
    [Abstract] [Full Text] [Related]

  • 15. Ranibizumab and stroke.
    Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T.
    Ophthalmology; 2010 Sep; 117(9):1860; author reply 1860-1. PubMed ID: 20816253
    [No Abstract] [Full Text] [Related]

  • 16. Towards a rational approach to combination therapy for neovascular age-related macular degeneration.
    Arroyo JG.
    Br J Ophthalmol; 2007 Feb; 91(2):130-1. PubMed ID: 17244655
    [Abstract] [Full Text] [Related]

  • 17. Age-related macular degeneration.
    Brucker AJ.
    Retina; 2009 Jun; 29(6 Suppl):S2-4. PubMed ID: 19553791
    [Abstract] [Full Text] [Related]

  • 18. Avastin versus Lucentis: ethical issues in treatment of age-related macular degeneration.
    Klein RM, Klein RB.
    Retina; 2007 Jun; 27(9):1163-5. PubMed ID: 18046218
    [No Abstract] [Full Text] [Related]

  • 19. Anti-vascular endothelial growth factor strategies for the treatment of choroidal neovascularization from age-related macular degeneration.
    Barouch FC, Miller JW.
    Int Ophthalmol Clin; 2004 Jun; 44(3):23-32. PubMed ID: 15211174
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.